The National Institutes of Health has withdrawn renewal grant applications for the Consortium of Eosinophilic Gastrointestinal Disease Researchers.
Patient advocacy organizations, including the American Academy of Allergy, Asthma & Immunology, have called on Congress and the Rare Disease Congressional Caucus to reinstate funding, according to an April 21 press release.
“The withdrawal of the five-year renewal application for the Consortium of Eosinophilic Gastrointestinal Disease Researchers jeopardizes critical funding for the only clinical care network for eosinophilic gastroenteritis patients in the United States. The fact that this withdrawal was not due to scientific merit makes it even more egregious. Diagnostic and therapeutic research efforts will be halted, and the collapse of this infrastructure will be devastating to our patients. This is a dangerous national precedent,” said Carla Davis, MD, AAAAI president-elect and chair of the AAAAI scientific community task force for allergy/immunology research.
The NIH withdrew funding for the “critically important” program in early April, citing new policy changes within the organization.
This grant dismissal will affect millions of Americans involved in clinical trials and immediately halt life-saving research that supports patients living with these diseases, according to the release.
The post NIH defunds ‘critically important’ GI program appeared first on Becker’s ASC.
